Sarissa Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Sarissa Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-101,362	Closed	-$598K	–	10
2017 Q1	$598K	Sell	101,362 -68,638	-40%	-$496K	0.24%	11
2016 Q4	$917K	Sell	170,000 -30,000	-15%	-$200K	0.25%	10
2016 Q3	$1.78M	Hold	200,000	–	–	0.41%	14
2016 Q2	$1.92M	Sell	200,000 -31,376	-14%	-$303K	0.55%	15
2016 Q1	$2.13M	Hold	231,376	–	–	0.47%	14
2015 Q4	$2.92M	Hold	231,376	–	–	0.57%	13
2015 Q3	$2.8M	Hold	231,376	–	–	0.69%	15
2015 Q2	$4.03M	Sell	231,376 -25,700	-10%	-$462K	0.93%	13
2015 Q1	$3.73M	Hold	257,076	–	–	0.79%	14
2014 Q4	$2.16M	Hold	257,076	–	–	0.76%	11
2014 Q3	$2.85M	Hold	257,076	–	–	1.1%	12
2014 Q2	$4.7M	Hold	257,076	–	–	1.6%	9
2014 Q1	$3.84M	Hold	257,076	–	–	1.32%	9
2013 Q4	$4.73M	Buy	+257,076	New	+$5.15M	1.77%	12

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Sarissa Capital Management's AVEO Position: Q2 2017 in Review

Sarissa Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2017, closing a stake of 101,362 shares — an estimated $598K sold.

Sarissa Capital Management first reported a position in AVEO in Q4 2013 and held it in 14 quarters. The position peaked at $4.73M in Q4 2013. 49 funds tracked by Wall St. Rank hold AVEO as of Q2 2017.

Sarissa Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Sarissa Capital Management sold 101,362 AVEO Pharmaceuticals, Inc. shares in Q2 2017, an estimated $598K.
Sarissa Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 14 quarters.
Sarissa Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $4.73M in Q4 2013.
49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2017.

Based on Sarissa Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.